Drugs / IMCY-0141
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05417269 | Apr 2022 → May 2025 | relapsing-remitting multiple sclerosis | Imcyse SA | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMCY-0141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05417269 ↗ |
| Modality | Peptide | “small synthetic peptide” NCT05417269 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) administration” NCT05417269 ↗ |